Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Coronary No-Reflow after Primary Percutaneous Coronary Intervention—Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy
G Ndrepepa, A Kastrati - Journal of clinical medicine, 2023 - mdpi.com
Coronary no-reflow (CNR) is a frequent phenomenon that develops in patients with ST-
segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is …
segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is …
The role and mechanisms of microvascular damage in the ischemic myocardium
BH Zhao, A Ruze, L Zhao, QL Li, J Tang… - Cellular and Molecular …, 2023 - Springer
Following myocardial ischemic injury, the most effective clinical intervention is timely
restoration of blood perfusion to ischemic but viable myocardium to reduce irreversible …
restoration of blood perfusion to ischemic but viable myocardium to reduce irreversible …
Pan-immune-inflammation value is independently correlated to impaired coronary flow after primary percutaneous coronary intervention in patients with ST-segment …
F Şen, A Kurtul, Ö Bekler - The American Journal of Cardiology, 2024 - Elsevier
Immune-inflammatory biomarkers have been shown to be correlated with impaired coronary
flow (ICF) in ST-segment elevation myocardial infarction. In this study, we assessed the …
flow (ICF) in ST-segment elevation myocardial infarction. In this study, we assessed the …
The HbA1c/C-peptide ratio is associated with the no-reflow phenomenon in patients with ST-elevation myocardial infarction
Currently, the gold standard treatment for ST-elevation myocardial infarction (STEMI) is
primary percutaneous coronary intervention (pPCI), but even after successful pPCI, a …
primary percutaneous coronary intervention (pPCI), but even after successful pPCI, a …
Assessment of coronary microcirculation alterations in a porcine model of no-reflow using ultrasound localization microscopy: a proof of concept study
O Demeulenaere, P Mateo, R Ferrera, PM Chiaroni… - …, 2023 - thelancet.com
Background Coronary microvascular obstruction also known as no-reflow phenomenon is a
major issue during myocardial infarction that bears important prognostic implications …
major issue during myocardial infarction that bears important prognostic implications …
[HTML][HTML] Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
S Kozhukhov, A Parkhomenko, Y Lutay… - Hellenic Journal of …, 2024 - Elsevier
Objective Myocardial infarction (MI) is one of the leading causes of death in the world. Early
myocardial reperfusion improves acute MI survival. Bioflavonoid quercetin is known to have …
myocardial reperfusion improves acute MI survival. Bioflavonoid quercetin is known to have …
The association between atherogenic index of plasma and no-reflow phenomenon in acute coronary syndrome
İE Çelik, S Öztürk, M Yarlıoğlu… - Anatolian Journal of …, 2023 - pmc.ncbi.nlm.nih.gov
Background: The atherogenic index of plasma (AIP) is a biomarker of plasma atherogenicity.
Elevated AIP is linked with adverse cardiac events. We sought to examine the association of …
Elevated AIP is linked with adverse cardiac events. We sought to examine the association of …
The HALP score predicts no-reflow phenomenon and long-term prognosis in patients with ST-segment elevation myocardial infarction after primary percutaneous …
H Liu, F Zhang, Y Li, L Liu, X Song, J Wang… - Coronary Artery …, 2024 - journals.lww.com
Results Long-term mortality was significantly higher in patients with HALP scores lower than
40.11 than in those higher than 40.11. The optimal cutoff value of HALP score for predicting …
40.11 than in those higher than 40.11. The optimal cutoff value of HALP score for predicting …
Newly defined biomarker for the no reflow phenomenon in patients with non-ST elevation acute coronary syndrome; uric acid to creatinine ratio
M Kalyoncuoglu, A Gumusdag, H Oguz, H Ogur… - Acta …, 2025 - Taylor & Francis
Background The present study aimed to investigate whether newly defined serum uric acid
(SUA) to serum creatinine ratio (SUA/SCr) predicts no-reflow phenomenon (NRP) …
(SUA) to serum creatinine ratio (SUA/SCr) predicts no-reflow phenomenon (NRP) …
Tongmai Yangxin pill alleviates myocardial no-reflow by activating GPER to regulate HIF-1α signaling and downstream potassium channels
T Chen, Y Zhang, M Chen, P Yang, Y Wang… - Pharmaceutical …, 2023 - Taylor & Francis
Abstract Context The Tongmai Yangxin pill (TMYX) has potential clinical effects on no-reflow
(NR); however, the effective substances and mechanisms remain unclear. Objective This …
(NR); however, the effective substances and mechanisms remain unclear. Objective This …